

US Cancer Antibodies Market, Drug Sales, Patent & Clinical Trials Outlook 2028

<https://marketpublishers.com/r/UD4629618DE3EN.html>

Date: February 2022

Pages: 360

Price: US\$ 3,600.00 (Single User License)

ID: UD4629618DE3EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

US Cancer Antibodies Market, Drug Sales, Patent & Clinical Trials Outlook 2028 Report Highlights:

US Cancer Antibodies Market Opportunity: > US\$ 85 Billion by 2028

US Cancer Antibodies Market To Witness More Than 200% Absolute Growth

Current & Future market Projections by Drugs & Therapeutic Class

Clinical Trials Insight On by Company, Indication, Patient Segment and Phase

Immune Checkpoint Inhibitors Dominating The Antibodies Sales: > 15 Billion In 2021

Insight on FDA Approved 61 Cancer Antibodies Available in US Market

Price, Dosage, Patent and Sales Insight on Cancer Antibodies Available In Market

US Cancer Biosimilar Market Opportunity Insight

In last few years, therapeutic antibodies have gained maximum share in the US cancer therapeutics market. Their ability to specifically target the antigens on cancer has

enabled the development of several targeted therapies. Further, advancement in the field of biotechnology has also led to development of new generation therapeutic agents. To date, several modalities of therapeutic antibodies including monoclonal antibodies, bispecific antibodies, antibody drug conjugates, and radiolabelled antibodies have been approved by US FDA which has shown robust response in the market. These are indicated for the management of several cancers including breast cancer, lung cancer, blood cancer, colorectal cancer, and other malignancies.

In 2021, immune checkpoint inhibitors segment hold the maximum share in the US cancer antibody market owing to their unique mechanism of action. The immune checkpoint inhibitors act by blocking the checkpoint protein, which are responsible for the prevention of cancer cells from the action of immune system. To date, 8 immune checkpoint inhibitors have entered the US market which is showing increasing sales every year. Apart from this, researchers are also evaluating other immune checkpoint including LAG-3, TIGIT, and others which are mainly present in clinical development. Relatlimab developed by Bristol Myers Squibb is a potential LAG-3 inhibitor which is expected to gain approval in market in March 2022, thus further boosting the growth of this segment during the forecast period.

The promising response of antibody therapeutics in the management of several cancers has gained a lot of attention from researchers. To date, more than 1000 clinical trials are ongoing in US, which are evaluating the role of therapeutic antibodies as monotherapy or combinational therapy in the management of cancer. For instance, researchers have developed next generation trispecific antibodies and bispecific antibody conjugate which are in initial stages of clinical development. The large number of clinical and preclinical studies suggests the promising future of antibody therapeutics in various cancers.

US is currently dominating the global cancer antibody market is mainly attributed to the surge in prevalence of cancer and rising awareness among population regarding the availability of targeted therapies. In addition, presence of major pharmaceutical companies in the region and rising investments by them also propels the growth of market during the forecast period. Apart from this, FDA also grants special designations to expedite the drug development process including orphan drug designation, fast track designation, breakthrough therapy designation, and others. Furthermore, development of favorable reimbursement policies also enhances their uptake of novel antibody therapeutics in the region.

The US cancer antibody therapeutic market is highly crowded and consists of several

key players including Novartis, Amgen, Pfizer, Gilead Sciences, AstraZeneca, Bristol Myers Squibb, among others. For instance in 2021, Exelixis and Invenra have extended their discovery and licensing partnership to include 20 more oncology targets for multi-specific antibodies, antibody-drug conjugates, and the development of other biologic candidates. Further, AbbVie and I-Mab also announced collaboration for the development and commercialization of lemozoparlimab (also known as TJC4), an innovative anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. In addition, the two partners have the potential to expand the collaboration to additional transformative therapies.

As per our report findings, the US cancer antibody market is expected to surpass US\$ 85 Billion by 2028. Rise in incidence of various cancer conditions, increase in popularity of advance therapies, and surge in geriatric population are the key factors driving the growth of the market. However, high cost involved in new drug development coupled with threat of failure and adverse effects associated with cancer antibody therapies is expected to restrain the growth of the market. Conversely, high potential of emerging economies and higher number of potential drugs in pipeline are expected to provide new opportunities for market players in future.

Contents

1. US CANCER ANTIBODIES MARKET ANALYSIS

- 1.1 Current Market Scenario
- 1.2 Leading Cancer Antibodies Available in Market

2. US CANCER ANTIBODIES MARKET BY THERAPEUTIC CLASS

- 2.1 Immune Checkpoint Inhibitors
- 2.2 US Bispecific Antibody Market
- 2.3 US Antibody Drug Conjugate Market
- 2.4 Other Cancer Antibody Therapeutics
 - 2.4.1 VEGF/VEGFR Inhibiting Antibodies
 - 2.4.2 D20 Targeting Antibodies
 - 2.4.3 CD38 Targeting Antibodies
 - 2.4.4 EGFR Inhibiting Antibodies

3. US BREAST CANCER ANTIBODIES MARKET

- 3.1 Current Market Scenario
- 3.2 Leading Breast Cancer Antibodies Sales Insight

4. US BLOOD CANCER ANTIBODY MARKET

- 4.1 Current Market Scenario
- 4.2 Leading Blood Cancer Targeting Antibodies Sales Insight

5. US LUNG CANCER ANTIBODY MARKET

- 5.1 Current Market Scenario
- 5.2 Leading Antibodies for Lung Cancer Sales Insight

6. US COLORECTAL CANCER ANTIBODIES MARKET OVERVIEW

7. US CANCER BIOSIMILAR MARKET

- 7.1 Current Market Scenario
- 7.2 Market Opportunity & Future Forecast

8. US CANCER ANTIBODIES CLINICAL TRIALS OVERVIEW

- 8.1 By Company
- 8.2 By Indication
- 8.3 By Patient Segment
- 8.4 By Phase

9. US HER2 INHIBITING ANTIBODIES - AVAILABILITY, DOSAGE, PATENT, PRICE & SALES ANALYSIS

- 9.1 Trastuzumab (Herceptin)
- 9.2 Trastuzumab Biosimilar (Ontruzant)
- 9.3 Trastuzumab Biosimilar (Ogivri)
- 9.4 Trastuzumab Biosimilar (Herzuma)
- 9.5 Trastuzumab Biosimilar (Trazimera)
- 9.6 Trastuzumab Biosimilar (Kanjinti)
- 9.7 Trastuzumab & Hyaluronidase Injection (Herceptin Hylecta)
- 9.8 Pertuzumab (Perjeta)
- 9.9 Margetuximab (Margenza)

10. US VEGF/VEGFR INHIBITING ANTIBODIES -AVAILABILITY, DOSAGE, PATENT, PRICE & SALES ANALYSIS

- 10.1 Bevacizumab (Avastin)
- 10.2 Bevacizumab Biosimilar (Mvasi)
- 10.3 Bevacizumab Biosimilar (Zirabev)
- 10.4 Ramucirumab (Cyramza)

11. US ANTIBODY-DRUG CONJUGATES - AVAILABILITY, DOSAGE, PATENT, PRICE & SALES ANALYSIS

- 11.1 Ado-Trastuzumab Emtansine (Kadcyla)
- 11.2 Fam-Trastuzumab Deruxtecan (Enhertu)
- 11.3 Trodelvy (Sacituzumab Govitecan-hziy)
- 11.4 Moxetumomab Pasudotox-tdfk (Lumoxiti)
- 11.5 Inotuzumab Ozogamicin (Besponsa)
- 11.6 Gemtuzumab Ozogamicin (Mylotarg)
- 11.7 Belantamab Mafodotin-blmf (Blenrep)

- 11.8 Brentuximab Vedotin (Adcetris)
- 11.9 Polatuzumab Vedotin-piiq (Polivy)
- 11.10 Enfortumab Vedotin (Padcev)
- 11.11 Loncastuximab Tesirine (Zynlonta)
- 11.12 Tisotumab Vedotin (Tivdak)

12. US CD20-DIRECTED ANTIBODY - AVAILABILITY, DOSAGE, PATENT, PRICE & SALES ANALYSIS

- 12.1 Rituximab (Mabthera/Rituxan)
- 12.2 Rituximab Biosimilar (Truxima)
- 12.3 Rituximab Biosimilar (Riabni)
- 12.4 Rituximab Biosimilar (Ruxience)
- 12.5 Rituximab/Hyaluronidase (Rituxan Hycela)
- 12.6 Obinutuzumab (Gazyva)
- 12.7 Ofatumumab (Arzerra)

13. US BISPECIFIC ANTIBODIES - AVAILABILITY, DOSAGE, PATENT, PRICE & SALES ANALYSIS

- 13.1 Blinatumomab (Blincyto)
- 13.2 Amivantamab (Rybrevant)

14. CD52 MONOCLONAL ANTIBODIES - AVAILABILITY, DOSAGE, PATENT, PRICE & SALES ANALYSIS

- 14.1 Alemtuzumab (Lemtrada)

15. CD38 MONOCLONAL ANTIBODIES - AVAILABILITY, DOSAGE, PATENT, PRICE & SALES ANALYSIS

- 15.1 Isatuximab-irfc (Sarclisa)
- 15.2 Darzalex (Daratumumab)
- 15.3 Darzalex Faspro (Daratumumab/Hyaluronidase)

16. IMMUNE CHECKPOINT INHIBITOR - AVAILABILITY, DOSAGE, PATENT, PRICE & SALES ANALYSIS

- 16.1 Pembrolizumab (Keytruda)

- 16.2 Ipilimumab (Yervoy)
- 16.3 Nivolumab (Opdivo)
- 16.4 Durvalumab (Imfinzi) – Urothelial Carcinoma
- 16.5 Avelumab (Bavencio)
- 16.6 Atezolizumab (Tecentriq)
- 16.7 Cemiplimab (Libtayo)
- 16.8 Dostarlimab (Jemperli)

17. EGFR INHIBITORS - AVAILABILITY, DOSAGE, PATENT, PRICE & SALES ANALYSIS

- 17.1 Cetuximab (Erbitux)
- 17.2 Portrazza (Necitumumab)
- 17.3 Nimotuzumab
- 17.4 Panitumumab (Vectibix)

18. COMBINATIONAL ANTIBODIES - AVAILABILITY, DOSAGE, PRICE & SALES ANALYSIS

- 18.1 Trastuzumab, Pertuzumab, & Hyaluronidase (Phesgo)

19. OTHERS CANCER TARGETING ANTIBODIES OF US - AVAILABILITY, DOSAGE, PATENT, PRICE & SALES ANALYSIS

- 19.1 Tagraxofusp (Elzonris)
- 19.2 Tafasitamab (Monjuvi)
- 19.3 Mogamulizumab-kpkc (Poteligeo)
- 19.4 Denosumab (Xgeva)
- 19.5 Empliciti (Elotuzumab)
- 19.6 Unituxin (dinutuximab) Neuroblastoma
- 19.7 Satumomab
- 19.8 Naxitamab-gqgk (Danyelza)
- 19.9 Iodine I 131 Derlotuximab Biotin
- 19.10 Capromab Pendetide (ProstaScint)

20. COMPETITIVE LANDSCAPE

- 20.1 Amgen
- 20.2 AryoGen Pharmed

- 20.3 AstraZeneca plc
- 20.4 BIOCAD
- 20.5 Boehringer Ingelheim
- 20.6 Bristol Mayer Squibb
- 20.7 Daiichi Sankyo Company
- 20.8 Genentech
- 20.9 Immunomedics
- 20.10 Innovent Biologics
- 20.11 Jassen Pharmaceuticals
- 20.12 MacroGenics
- 20.13 mAbxience
- 20.14 Mylan
- 20.15 Outlook Therapeutics
- 20.16 Pfizer
- 20.17 Prestige Biopharma
- 20.18 Roche
- 20.19 Samsung Bio
- 20.20 Seagen

List Of Figures

LIST OF FIGURES

Figure 1-1: US – Estimated Newly Diagnosed Cancer Cases (Million), 2020, 2025 & 2030

Figure 1-2: US – Estimated Cancer Deaths, 2020, 2025 & 2030

Figure 1-3: Global – Cancer Antibody Market Opportunity (US\$ Billion), 2022 - 2028

Figure 1-4: Global – Cancer Therapeutics Market Opportunity (US\$ Billion), 2022 - 2028

Figure 1-5: US – Cancer Antibodies Market (US\$ Billion), 2021 - 2028

Figure 1-6: US – Keytruda Annual Sales Value (US\$ Billion), 2020 & 2021

Figure 1-7: US - Opdivo Annual Sales Value (US\$ Billion), 2020 & 2021

Figure 1-8: US - Tecentriq Annual Sales Value (US\$ Billion), 2020 & 2021

Figure 1-9: US - Rituxan Annual Sales Value (US\$ Billion), 2020 & 2021

Figure 1-10: US - Xgeva Annual Sales Value (US\$ Billion), 2020 & 2021

Figure 1-11: US - Perjeta Annual Sales Value (US\$ Billion), 2020 & 2021

Figure 1-12: US - Imfinzi Annual Sales Value (US\$ Billion), 2020 & 2021

Figure 1-13: US - Avastin Annual Sales Value (US\$ Billion), 2020 & 2021

Figure 1-14: US - Herceptin Annual Sales Value (US\$ Billion), 2020 & 2021

Figure 2-1: Major Types of Cancer Targeting Antibodies

Figure 2-2: Global – Immune Checkpoint Inhibitors Market by Region (US\$ Billion), 2021

Figure 2-3: Global – Immune Checkpoint Inhibitors Market by Region (%), 2021

Figure 2-4: US – Immune Checkpoint Inhibitors Market Opportunity (US\$ Billion), 2022 - 2028

Figure 2-5: Global – Immune Checkpoint Inhibitors Market Opportunity (US\$ Billion), 2022 - 2028

Figure 2-6: US – Sales Value of Leading Immune Checkpoint Inhibitors (US\$ Billion), 2021

Figure 2-7: US – Immune Checkpoint Inhibitors Market Size by Product (%), 2021

Figure 2-8: Global – Bispecific Cancer Antibody Market by Region (US\$ Million), 2021

Figure 2-9: Global – Bispecific Antibody Market by Region (%), 2021

Figure 2-10: US – Bispecific Antibody Market (US\$ Million), 2016-2020

Figure 2-11: US – Bispecific Antibody Market Opportunity (US\$ Million), 2022 - 2028

Figure 2-12: Global – Bispecific Antibody Market Opportunity (US\$ Million), 2022 - 2028

Figure 2-13: Global – Antibody Drug Conjugate Market by Region (US\$ Million), 2021

Figure 2-14: Global – Antibody Drug Conjugate Inhibitors Market by Region (%), 2021

Figure 2-15: US – Antibody Drug Conjugate Inhibitors Market Opportunity (US\$ Million), 2022 - 2028

Figure 2-16: Global – Antibody Drug Conjugate Inhibitors Market Opportunity (US\$ Million), 2022 - 2028

Figure 2-17: US – Sales Value of Leading Antibody Drug Conjugates (US\$ Million), 2021

Figure 2-18: US – Antibody Drug Conjugate Inhibitors Market Size by Product (%), 2021

Figure 2-19: Global – VEGF/VEGFR Inhibitor Antibody Market by Region (US\$ Billion), 2021

Figure 2-20: Global – VEGF/VEGFR Inhibitor Antibody Market by Region (%), 2021

Figure 2-21: US – VEGF/VEGFR Inhibitor Antibody Market Opportunity (US\$ Billion), 2022 - 2028

Figure 2-22: Global – VEGF/VEGFR Inhibitor Antibody Market Opportunity (US\$ Billion), 2020 - 2028

Figure 2-23: US – Sales Value of Leading VEGF/VEGFR Inhibitor Antibodies (US\$ Million), 2021

Figure 2-24: US – CD20 Inhibitor Cancer Antibody Market Opportunity (US\$ Billion), 2022 - 2028

Figure 2-25: US – Sales Value of Leading CD20 Inhibitor Cancer Antibody (US\$ Million), 2020

Figure 2-26: US – Sales Value of Leading CD20 Inhibitor Cancer Antibody (%), 2021

Figure 2-27: US – CD38 Inhibitor Cancer Antibody Market Opportunity (US\$ Billion), 2022 - 2028

Figure 2-28: US – Sales Value of Leading CD38 Inhibitor Cancer Antibody (US\$ Million), 2021

Figure 2-29: US – Sales Value of Leading CD38 Inhibitor Cancer Antibody (%), 2021

Figure 3-1: US – Estimated Newly Diagnosed Breast Cancer Cases, 2020, 2025 & 2030

Figure 3-2: US – Estimated Breast Cancer Deaths, 2020, 2025 & 2030

Figure 3-3: US – Sales of Leading Breast Cancer Antibodies (US\$ Billion), 2021

Figure 3-4: US – Sales of Leading Breast Cancer Antibodies (US\$ Billion), 2020

Figure 4-1: US – Estimated Newly Diagnosed Blood Cancer Cases by Type, 2020

Figure 4-2: US – Estimated Blood Cancer Deaths by Type, 2020

Figure 4-3: US – Sales of Leading Blood Cancer Antibodies (US\$ Billion), 2021

Figure 4-4: US – Sales of Leading Blood Cancer Antibodies (US\$ Billion), 2020

Figure 5-1: US – Estimated Newly Diagnosed Lung Cancer Cases, 2020, 2025 & 2030

Figure 5-2: US – Estimated Lung Cancer Deaths, 2020, 2025 & 2030

Figure 5-3: US – Sales of Leading Lung Cancer Antibodies (US\$ Billion), 2021

Figure 5-4: US – Sales of Leading Lung Cancer Antibodies (US\$ Billion), 2020

Figure 6-1: US – Estimated Newly Diagnosed Colon Cancer Cases, 2020, 2025 & 2030

Figure 6-2: US – Estimated Colon Cancer Deaths, 2020, 2025 & 2030

Figure 6-3: US – Estimated Newly Diagnosed Rectum Cancer Cases, 2020, 2025 &

2030

Figure 6-4: US – Estimated Rectum Cancer Deaths, 2020, 2025 & 2030

Figure 6-5: US – Colorectal Cancer Therapeutics Market Opportunity (US\$ Billion), 2021 - 2028

Figure 7-1: US – Average Price for 150mg Branded & Biosimilar Trastuzumab (US\$), February'2022

Figure 7-2: US – Average Price for 4ml Branded & Biosimilar Bevacizumab (US\$), February'2022

Figure 7-3: US – Average Price for 16ml Branded & Biosimilar Bevacizumab (US\$), February'2022

Figure 7-4: US – Average Price for 10ml Branded & Biosimilar Rituximab (US\$), February'2022

Figure 7-5: US – Average Price for 50ml Branded & Biosimilar Rituximab (US\$), February'2022

Figure 7-6: US – Estimated Patent Expiration Year of Cancer Antibodies

Figure 7-7: US – Cancer Biosimilar Antibody Market Size by Product (US\$ Million), 2021

Figure 7-8: US – Cancer Biosimilar Antibody Market Size by Product (%), 2021

Figure 7-9: US – Rituxan Biosimilar Market Size by Product (US\$ Million), 2021

Figure 7-10: US – Rituxan Market Size by Product (%), 2021

Figure 7-11: US – Bevacizumab Biosimilar Market Size by Product (US\$ Million), 2021

Figure 7-12: US – Bevacizumab Market Size by Product (%), 2021

Figure 7-13: US – Trastuzumab Biosimilar Market Size by Product (US\$ Million), 2020

Figure 7-14: US – Trastuzumab Market Size by Product (%), 2020

Figure 7-15: US – Cancer Biosimilar Antibody Market Opportunity (US\$ Billion), 2021 - 2028

Figure 7-16: US – Zirabev Market Opportunity (US\$ Million), 2021 - 2028

Figure 7-17: US – Mvasi Market Opportunity (US\$ Million), 2021 - 2028

Figure 7-18: US – Rituximab Biosimilar Market Opportunity (US\$ Million), 2021 - 2028

Figure 7-19: US – Kanjinti Market Opportunity (US\$ Million), 2021 - 2028

Figure 7-20: US – Trastuzumab Biosimilar Market Opportunity (US\$ Million), 2020 - 2026

Figure 8-1: US - Cancer Antibodies Clinical Pipeline by Company (Number of Drugs), 2022 till 2028

Figure 8-2: US - Cancer Antibodies Clinical Pipeline by Indication (Number of Drugs), 2022 till 2028

Figure 8-3: US - Cancer Antibodies Clinical Pipeline by Patient Segment (Number of Drugs), 2022 till 2028

Figure 8-4: US - Cancer Antibodies Clinical Pipeline by Phase (Number of Drugs), 2022 till 2028

- Figure 9-1: Herceptin – Approval Year by Cancer Type
- Figure 9-2: Herceptin – Price for a Supply of 10 & Price for Single 150mg Powder for Injection (US\$), February'2022
- Figure 9-3: Herceptin – Initial & Maintenance Dose for Breast Cancer Treatment (mg/kg)
- Figure 9-4: Herceptin – Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Breast Cancer (US\$), February'2022
- Figure 9-5: Herceptin – Initial & Maintenance Dose for Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (mg/kg)
- Figure 9-6: Herceptin – Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (US\$), February'2022
- Figure 9-7: US - Herceptin Annual Sales Value (US\$/CHF Million), 2018 - 2021
- Figure 9-8: US - Herceptin Quarterly Sales Value (US\$/CHF Million), 2021
- Figure 9-9: Ontruzant – Price for 150mg & 420mg Powder for Injection (US\$), February'2022
- Figure 9-10: Ontruzant – Initial & Maintenance Dose for Breast Cancer (mg/kg/Week)
- Figure 9-11: Ontruzant – Average Cost of Initial Week, Maintenance Week & Annual (US\$), February'2022
- Figure 9-12: Ontruzant – Initial & Maintenance Dose for Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (mg/kg)
- Figure 9-13: Ontruzant – Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (US\$), February'2022
- Figure 9-14: Ogivri – Price for 150mg & 420mg Powder for Injection (US\$), February'2022
- Figure 9-15: Ogivri – Initial & Maintenance Dose for Breast Cancer (mg/kg/Week)
- Figure 9-16: Ogivri – Average Cost of Initial Week, Maintenance Week & Annual (US\$), February'2022
- Figure 9-17: Ogivri – Initial & Maintenance Dose for Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (mg/kg)
- Figure 9-18: Ogivri – Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (US\$), February'2022
- Figure 9-19: Herzuma – Price for 150mg & 420mg Powder for Injection (US\$), February'2022
- Figure 9-20: Herzuma – Initial & Maintenance Dose for Breast Cancer (mg/kg/Week)
- Figure 9-21: Herzuma – Average Cost of Initial Week, Maintenance Week & Annual (US\$), February'2022
- Figure 9-22: Herzuma – Initial & Maintenance Dose for Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (mg/kg)

Figure 9-23: Herzuma – Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (US\$), February'2022

Figure 9-24: Trazimera – Price for 150mg & 420mg Powder for Injection (US\$), February'2022

Figure 9-25: Trazimera – Initial & Maintenance Dose for Breast Cancer (mg/kg/Week)

Figure 9-26: Trazimera – Average Cost of Initial Week, Maintenance Week & Annual treatment (US\$), February'2022

Figure 9-27: Trazimera – Initial & Maintenance Dose for Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (mg/kg)

Figure 9-28: Trazimera – Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer, Gastric & Esophageal Carcinoma (US\$), February'2022

Figure 9-29: Kanjinti – Price for 150mg & 420mg Powder for Injection (US\$), February'2022

Figure 9-30: Kanjinti – Initial & Maintenance Dose for Breast Cancer (mg/kg/Week)

Figure 9-31: Kanjinti – Average Cost of Initial Week, Maintenance Week & Annual Treatment of Breast Cancer (US\$), February'2022

Figure 9-32: Kanjinti – Initial & Maintenance Dose for of Adjuvant Breast Cancer, Gastric Cancer & Esophageal Carcinoma (mg/kg/Week)

Figure 9-33: Kanjinti – Average Cost of Initial Week, Maintenance Week & Annual Treatment of Adjuvant Breast Cancer, Gastric Cancer & Esophageal Carcinoma (US\$), February'2022

Figure 9-34: US – Kanjinti Annual Sales (US\$ Million), 2019 - 2021

Figure 9-35: US – Kanjinti Quarterely Sales (US\$ Million), 2021

Figure 9-36: US – Kanjinti Quarterely Sales (US\$ Million), 2020

Figure 9-37: Herceptin Hylecta – Price for 5ml & Price Per ml of Subcutaneous Solution for Injection (US\$), February'2022

Figure 9-38: Herceptin Hylecta – Duration of Single Treatment Cycle & Full Treatment (week)

Figure 9-39: Perjeta - Approval Year by Cancer Type

Figure 9-40: Perjeta – Patent Expiration Year by Region

Figure 9-41: Perjeta – Price for a Supply of 14 ml and Price Per ml of Intravenous Solution (US\$), February'2022

Figure 9-42: Perjeta – Initial & Maintenance Dose for Breast Cancer Treatment (mg/3 weeks)

Figure 9-43: Perjeta – Minimum & Maximum Treatment Cost for Breast Cancer (US\$), February'2022

Figure 9-44: Perjeta – Minimum & Maximum Treatment Cost of Neoadjuvant Breast

Cancer Treatment (US\$), February'2022

Figure 9-45: US - Perjeta Annual Sales Value (US\$/CHF Million), 2018 - 2021

Figure 9-46: US - Perjeta Quarterly Sales Value (US\$/CHF Million), 2021

Figure 9-47: Margenza – Price for a Supply of 10 ml and Price Per ml of Intravenous Solution (US\$), February'2022

Figure 9-48: Margenza – Price for a Supply of 40 ml and Price Per ml of Intravenous Solution (US\$), February'2022

Figure 9-49: Margenza – Average Cost of Single Cycle & Annual Treatment (US\$), February'2022

Figure 9-50: US – Margenza Quarterely Sales (US\$ Million), Q1-Q3'2021

Figure 10-1: Avastin – FDA Approval Year by Indication

Figure 10-2: Avastin – Price for a Supply of 10 & Price for Single 4ml Solution for Injection (US\$), February'2022

Figure 10-3: Avastin – Price for a Supply of 10 & Price for Single 16ml Solution for Injection (US\$), February'2022

Figure 10-4: Avastin – Pice for Single Treatment Cycle & Annual Treatment of Breast Cancer (US\$), February'2022

Figure 10-5: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for NSCLC & Metastatic Cervical Cancer (US\$), February'2022

Figure 10-6: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US\$), February'2022

Figure 10-7: Avastin – Duration of Treatment of Recurrent Glioblastoma & Renal Cell Carcinoma as Combinational & Monotherapy (Weeks)

Figure 10-8: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US\$), February'2022

Figure 10-9: US - Perjeta Annual Sales Value (US\$/CHF Million), 2018 - 2021

Figure 10-10: US - Avastin Quarterly Sales Value (US\$ Billion), 2021

Figure 10-11: US - Avastin Quarterly Sales Value (US\$ Million), 2020

Figure 10-12: Mvasi - Price for 4ml Supply & Price Per ml of Intravenous Solution (US\$), February'2022

Figure 10-13: Mvasi - Price for 16 ml Supply & Price Per Unit of Intravenous Solution (US\$), February'2022

Figure 10-14: Mvasi – Cost of Single Treatment Cycle & Annual Treatment Cost for NSCLC & Metastatic Cervical Cancer (US\$), February'2022

Figure 10-15: Mvasi – Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US\$), February'2022

Figure 10-16: US - Mvasi Annual Sales Value (US\$ Million), 2019 - 2021

Figure 10-17: US – Kanjinti Quarterely Sales (US\$ Million), 2021

Figure 10-18: US - Mvasi Quarterly Sales Value (US\$ Million), 2020

Figure 10-19: Zirabev - Price for 4ml Supply & Price Per Unit of Intravenous Solution (US\$), February'2022

Figure 10-20: Zirabev - Price for 16 ml Supply & Price Per Unit of Intravenous Solution (US\$), February'2022

Figure 10-21: Zirabev – Cost of Single Treatment Cycle & Annual Treatment Cost for NSCLC & Metastatic Cervical Cancer (US\$), February'2022

Figure 10-22: Zirabev – Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US\$), February'2022

Figure 10-23: US – Zirabev Annual Sales (US\$ Million), 2020 & 2021

Figure 10-24: US – Zirabev Quarterely Sales (US\$ Million), 2021

Figure 10-25: US – Zirabev Quarterely Sales (US\$ Million), 2020

Figure 10-26: US – Ramucirumab FDA Approval Year by Indication

Figure 10-27: US - Ramucirumab Patent Approval & Expiration Year

Figure 10-28: Cyramza – Cost of Supply of 10ml & Per Unit Cost of Intravenous Solution (US\$), February'2022

Figure 10-29: Cyramza – Cost of Supply of 50ml & Per Unit Cost of Intravenous Solution (US\$), February'2022

Figure 10-30: Cyramza – Cost of Single Cycle & Annual Treatment Cost for NSCLC (US\$), February'2022

Figure 10-31: Cyramza – Cost of Single Cycle & Annual Treatment Cost for Gastric, Colorectal & Hepatocellular Carcinoma (US\$), February'2022

Figure 10-32: US – Cyramza Annual Sales (US\$ Million), 2017-2020

Figure 10-33: US – Cyramza Quarterely Sales (US\$ Million), 2021

Figure 10-34: US – Cyramza Quarterely Sales (US\$ Million), 2020

Figure 11-1: Kadcyla – FDA Approval Year for Late Stage & Early Stage HER2+ Breast Cancer

Figure 11-2: US - Price for Single Unit of Kadcyla 100mg & 160mg Intravenous Powder for Injection (US\$), February'2022

Figure 11-3: Kadcyla - Duration of Single Treatment Cycle & Full Treatment of Early Stage HER2+ Breast Cancer (Weeks)

Figure 11-4: Kadcyla – Average Cost of Single Treatment Cycle & Full Treatment of Early Stage HER2 Breast Cancer in Human with Average Weight (US\$), January'2022

Figure 11-5: Kadcyla – Recommended Dose After 1st & 2nd Dose Reduction (mg/m²)

Figure 11-6: US - Kadcyla Annual Sales Value (US\$/CHF Million), 2018 - 2021

Figure 11-7: US - Kadcyla Quarterly Sales Value (US\$ Billion), 2021

Figure 11-8: US - Kadcyla Quarterly Sales Value (US\$ Million), 2020

Figure 11-9: Enhertu – FDA Approval Year for Late Stage & Early Stage HER2+ Breast Cancer

Figure 11-10: US - Enhertu Patent Approval & Expiration Year

Figure 11-11: Enhertu – Recommended Dose by Cancer Type (mg/Kg)

Figure 11-12: Enhertu – Average Cost of Single Treatment Cycle & Annual Treatment Cost (US\$), February'2022

Figure 11-13: Enhertu – Recommended Dose & Dose after Reduction for Breast Cancer (mg/Kg)

Figure 11-14: Enhertu – Recommended Dose & Dose after Reduction for Gastric Cancer (mg/Kg)

Figure 11-15: US - Trodelvy FDA Approval by Indication

Figure 11-16: Trodelvy – FDA Approval & Patent Expiration Year

Figure 11-17: Trodelvy – Average Cost of Single Dose, Single Treatment Cycle & Annual Treatment Cost (US\$), February'2022

Figure 11-18: Trodelvy – Recommended Dose & Dose after Reduction (mg/Kg)

Figure 11-19: US – Trodelvy Annual Sales (US\$ Million), 2020 & 2021

Figure 11-20: US - Trodelvy Quarterly Sales Value (US\$ Million), 2021

Figure 11-21: Lumoxiti – Year of Orphan Designation, FDA Approval & Patent Expiration

Figure 11-22: Lumoxiti – Duration of Single Treatment Cycle & Full Treatment (Weeks)

Figure 11-23: Lumoxiti – Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia (US\$), February'2022

Figure 11-24: Besponsa – Duration of Initial Treatment Cycle & Subsequent Cycles (Days)

Figure 11-25; Besponsa – Recommended Dose for 1st, 8th & 15th Day of Initial Treatment Cycle (mg/m²)

Figure 11-26: Besponsa – Cost of Single Unit & Full Cost of Initial Treatment Cycle (US\$), February'2022

Figure 11-27: Besponsa – Cost of Single Unit & Full Cost of Subsequent Treatment Cycle in Patient with CR (US\$), January'2022

Figure 11-28: Besponsa – Duration of Treatment of ALL – After & Without HSCT (Weeks)

Figure 11-29: US – Besponsa Annual Sales (US\$ Million), 2020 & 2021

Figure 11-30: US – Zirabev Quarterely Sales (US\$ Million), 2021

Figure 11-31: US – Zirabev Quarterely Sales (US\$ Million), 2020

Figure 11-32: Mylotarg – FDA Approval, Withdrawal & Re-Approval Year

Figure 11-33: Mylotarg – Number of Induction Cycle & Consolidation Cycle Required for Treatment of Newly Diagnosed De Novo CD33-positive AML

Figure 11-34: Mylotarg – Cost of Induction Cycle, Consolidation Cycles & Full Treatment Cost of Newly Diagnosed De Novo CD33-positive AML (US\$), February'2022

Figure 11-35: Mylotarg – Recommended Number of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 Positive AML

Figure 11-36: Mylotarg – Length of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 positive AML (Days)

Figure 11-37: Mylotarg – Recommended Dose of Initial Dose & Continuation Dose for Treatment of Newly Diagnosed CD-33 positive AML (mg/m²)

Figure 11-38: Mylotarg – Cost of Induction Phase & Continuation Phase & Full Treatment Cost of CD-33 positive AML (US\$), February'2022

Figure 11-39: Mylotarg – Cost of Single Dose & Full Treatment Cost of Relapsed & Refractory CD33 Positive AML, January'2022

Figure 11-40: US - Blenrep FDA Orphan Drug Designation & Approval Year

Figure 11-41: Blenrep – Average Cost of Single Treatment Cycle & Annual Treatment Cost (US\$), February'2022

Figure 11-42: Blenrep – Recommended Dose & Dose after Reduction (mg/Kg)

Figure 11-43: US - Blenrep Annual Sales Value (US\$/GBP Million), 2020 & 2021

Figure 11-44: US - Blenrep Quarter Sales Value (US\$/GBP Million), 2021

Figure 11-45: US - Blenrep Quarter Sales Value (US\$/GBP Million), Q3 & Q4'2020

Figure 11-46: US - Adcetris FDA Approval Year by Indication

Figure 11-47: Adcetris – FDA Approval & Patent Expiration Year

Figure 11-48: Adcetris – Duration of Single Treatment Cycle & Full Treatment of Stage III and IV Classical Hodgkin Lymphoma (Weeks)

Figure 11-49: Adcetris – Maximum Cost of Single Treatment Cycle & Full Treatment of Stage III and IV Classical Hodgkin Lymphoma (US\$), February'2022

Figure 11-50: Adcetris – Duration of Single Treatment Cycle & Full Treatment of Classical Hodgkin Lymphoma (Weeks)

Figure 11-51: Adcetris – Maximum Cost of Single Treatment Cycle & Full Treatment of Classical Hodgkin Lymphoma (US\$), February'2022

Figure 11-52: Adcetris – Maximum Cost of Single Treatment Cycle & Full Treatment of Previously Untreated Systemic ALCL or Other CD30 T-Cell Lymphomas (US\$), February'2022

Figure 11-53: Adcetris – Duration of Single Treatment Cycle & Full Treatment of Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (Weeks)

Figure 11-54: Adcetris – Maximum Cost of Single Treatment Cycle & Full Treatment of Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (US\$), February'2022

Figure 11-55: Polivy – Patent Issue & Expiration Year

Figure 11-56: US - Price for Single Unit of Polivy 30mg & 140mg Intravenous Powder for Injection (US\$), February'2022

Figure 11-57: Polivy - Duration of Single Treatment Cycle & Full Treatment (Weeks)

Figure 11-58: Polivy – Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia (US\$), February'2022

Figure 11-59: US - Polivy Annual Sales Value (US\$/CHF Million), 2019 - 2021

- Figure 11-60: US - Polivy Quarterly Sales Value (US\$ Billion), 2021
- Figure 11-61: US - Polivy Quarter Sales Value (US\$/CHF Million), 2020
- Figure 11-62: US - Padcev FDA Approval & Patent Expiration Year
- Figure 11-63: US - Price for Padcev 20mg & 30mg Intravenous Powder for Injection (US\$), February'2022
- Figure 11-64: Padcev – Average Cost of Single Dose, Single Treatment Cycle & Full Treatment (US\$), February'2022
- Figure 11-65: Padcev – Recommended Minimum Dose & Dose after Reduction for Urothelial Cancer (mg/Kg)
- Figure 11-66: Padcev – Recommended Maximum Dose & Dose after Reduction for Urothelial Cancer (mg)
- Figure 11-67: US - Padcev Annual Sales Value (US\$ Million), 2019 - 2020
- Figure 11-68: US - Padcev Quarterly Sales Value (US\$ Million), 2021
- Figure 11-69: US - Padcev Quarterly Sales Value (US\$ Million), 2020
- Figure 11-70: US - Zynlonta FDA Orphan Drug Designation Approval & Patent Exclusivity Year
- Figure 11-71: US - Zynlonta Orphan Drug Designation & FDA Approval Year
- Figure 11-72: Zynlonta - Orphan Drug Designation by Region
- Figure 11-73: Zynlonta – Average Cost of Single Treatment Cycle & Annual Treatment Cost (US\$), February'2022
- Figure 11-74: Zynlonta – Recommended Dose for Initial & Subsequent Cycles (mg/kg)
- Figure 11-75: Global - Zynlonta Quarterly Sales (US\$ Million), Q2 & Q3'2021
- Figure 11-76: Tivdak – Average Cost of Single Treatment Cycle & Annual Treatment Cost (US\$), February'2022
- Figure 11-77: Tivdak – Maximum Cost of Single Treatment Cycle & Annual Treatment Cost (US\$), February'2022
- Figure 11-78: Tivdak – Recommended Dose & Dose after Reduction (mg/Kg)
- Figure 12-1: Rituxan – FDA Approval Year by Indication
- Figure 12-2: Rituxan – Price for a Supply of 10 ml & Price Per ml of Solution for Injection (US\$), February'2022
- Figure 12-3: Rituxan – Price for a Supply of 50 ml & Price Per ml of Solution for Injection (US\$), February'2022
- Figure 12-4: Rituxan – Price for a Supply of 100 ml & Price Per ml of Solution for Injection (US\$), February'2022
- Figure 12-5: Rituxan – Average Minimum & Maximum Cost for Refractory CD20+ B-Cell NHL Management (US\$), February'2022
- Figure 12-6: Rituxan – Average Cost for Single Dose & Cost of Full Maintenance Phase for CLL (US\$), February'2022
- Figure 12-7: US - Rituxan Annual Sales Value (US\$/CHF Million), 2018 - 2021

Figure 12-8: US - Rituximab Quarterly Sales Value (US\$ Billion), 2021

Figure 12-9: US - Rituxan Quarterly Sales Value (US\$ Million), 2020

Figure 12-10: Truxima – Price for a Supply of 10 ml & Price Per ml of Solution for Injection (US\$), February'2022

Figure 12-11: Truxima – Price for a Supply of 50 ml & Price Per ml of Solution for Injection (US\$), February'2022

Figure 12-12: Truxima – Average Minimum & Maximum Cost for Refractory CD20+ B-Cell NHL Management (US\$), February'2022

Figure 12-13: Truxima – Average Cost for Single Dose & Cost of Full Maintenance Phase for CLL (US\$), February'2022

Figure 12-14: Riabni – Cost of Supply of 10ml & Per Unit Price of 10mg/ml Intravenous Solution (US\$), February'2022

Figure 12-15: Riabni – Cost of Supply of 50ml & Per Unit Price of 10mg/ml Intravenous Solution (US\$), February'2022

Figure 12-16: Riabni – Cost of 8 Cycles, 4 Cycles & Single Cycle for Management of NHL (US\$), February'2022

Figure 12-17: Ruxience – Cost of Supply of 10ml & Per Unit Price of 10mg/ml Intravenous Solution (US\$), February'2022

Figure 12-18: Ruxience – Cost of Supply of 50ml & Per Unit Price of 10mg/ml Intravenous Solution (US\$), February'2022

Figure 12-19: Ruxience – Cost of 8 Cycles, 4 Cycles & Single Cycle for Management of NHL (US\$), February'2022

Figure 12-20: Rituxan Hycela – Price for 11.7 ml Supply & Price Per ml of 23,400 units-1,400mg/11.7 ml Subcutaneous Solution (US\$), February'2022

Figure 12-21: Rituxan Hycela – Price for 13.4 ml Supply & Price Per ml of 26,800 units-1,600 mg/13.4ml Subcutaneous Solution (US\$), February'2022

Figure 12-22: Rituxan Hycela –Minimum & Maximum Duration of Follicular lymphoma Treatment (Weeks)

Figure 12-23: Rituxan Hycela – Average Minimum & Maximum Cost of Follicular lymphoma (US\$), February'2022

Figure 12-24: Rituxan Hycela – Duration of Single Treatment Cycle & Full Treatment of Previously Untreated Follicular lymphoma (weeks)

Figure 12-25: Rituxan Hycela – Average Minimum & Maximum Cost of Previously Untreated Follicular lymphoma (US\$), February'2022

Figure 12-26: Rituxan Hycela – Average Minimum & Maximum Cost of Diffuse Large B-Cell Lymphoma (US\$), February'2022

Figure 12-27: Rituxan Hycela – Duration of CLL Treatment (Weeks)

Figure 12-28: Rituxan Hycela - Cost of Single Treatment Cycle & Full Treatment of CLL (US\$), February'2022

Figure 12-29: Gazyva – Approval Year by Cancer Type

Figure 12-30: Gazyva – Price for 40ml Supply & Price Per ml of Intravenous Solution (US\$), February'2022

Figure 12-31: Gazyva – Recommended Dosing Schedule for Initial Treatment Cycle of CLL (mg)

Figure 12-32: Gazyva – Duration of Single Treatment Cycle & Full Treatment of CLL (Week)

Figure 12-33: Gazyva – Cost of Initial & Subsequent Treatment Cycle & Full Treatment Cost of CLL (US\$), February'2022

Figure 12-34: Gazyva – Minimum & Maximum Duration for Follicular Lymphoma Treatment (Week)

Figure 12-35: Gazyva – Minimum & Maximum Treatment Cost of Follicular Lymphoma (US\$), February'2022

Figure 12-36: Gazyva – Duration of Single Treatment Cycle & Full Treatment Using Monotherapy (Months), February'2022

Figure 12-37: Gazyva – Cost of Single Treatment Cycle & Full Treatment using Monotherapy (US\$), February'2022

Figure 12-38: US - Gazyva Annual Sales Value (US\$/CHF Million), 2019 - 2021

Figure 12-39: US - Gazyva Quarterly Sales Value (US\$ Billion), 2021

Figure 12-40: US - Gazyva Quarterly Sales Value (US\$/CHF Million), 2020

Figure 12-41: Arzerra – Price for a Supply of 15 ml, 5 ml and Price per ml of Intravenous Solution (US\$), February'2022

Figure 12-42: Arzerra – Price for a Supply of 50 ml & Price Per ml of Intravenous Solution (US\$), February'2022

Figure 12-43: Arzerra – Initial & Maintenance Dose for Previously Untreated CLL (mg), February'2022

Figure 12-44: Arzerra – Minimum & Maximum Treatment Duration for Previously Untreated CLL (Weeks), February'2022

Figure 12-45: Arzerra – Minimum & Maximum Treatment Cost for Previously Untreated CLL (US\$), February'2022

Figure 12-46: Arzerra – Initial & Maintenance Dose for Relapsed CLL (mg), February'2022

Figure 12-47: Arzerra – Minimum & Maximum Treatment Cost for Relapsed CLL (US\$), February'2022

Figure 12-48: Arzerra – Initial & Maintenance Dose for Refractory CLL (mg), February'2022

Figure 12-49: Arzerra – Treatment Duration for Refractory CLL (Weeks), February'2022

Figure 12-50: Arzerra – Minimum & Maximum Treatment Cost for Refractory CLL (US\$), February'2022

Figure 13-1: Blincyto - Number of Induction & Consolidation Cycles for Treatment of MRD+ B-cell precursor ALL, February'2022

Figure 13-2: Blincyto - Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD+ B-cell Precursor ALL (Days) , February'2022

Figure 13-3: Blincyto - Cost of Single Cycle & Full Treatment Cost of MRD+ B-cell precursor ALL (US\$), February'2022

Figure 13-4: Blincyto - Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL, February'2022

Figure 13-5: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks), February'2022

Figure 13-6: Blincyto - Cost of 1st & 2nd Induction Cycle for Treatment of Relapsed B-Cell Precursor ALL (US\$), February'2022

Figure 13-7: US – Blincyto Annual Sales (US\$ Million), 2019 - 2021

Figure 13-8: US – Blincyto Quarterely Sales (US\$ Million), 2021

Figure 13-9: US - Blincyto Quarterly Sales Value (US\$ Million), 2020

Figure 13-10: Rybrevant – Price for 7ml Supply & Price per Unit of 50mg/ml Intravenous Solution (US\$), February'2022

Figure 13-11: Rybrevant – Recommended Dose Per Cycle by Body Weight (mg)

Figure 13-12: Rybrevant – Dose Reduction in Patients with Weight Less Than 80Kg (mg)

Figure 13-13: Rybrevant – Dose Reduction in Patients with Weight More Than 80Kg (mg)

Figure 14-1: Lemtrada – Price for 1.2ml Supply & Price Per ml of Intravenous Solution (US\$), February'2022

Figure 14-2: Lemtrada – Cost of Single Dose & Single Treatment Cycle (US\$), February'2022

Figure 14-3: US - Lemtrada Annual Sales Value (US\$/EUR Million), 2019 - 2021

Figure 14-4: US - Lemtrada Quarterly Sales Value (US\$/EUR Million), 2021

Figure 14-5: US - Lemtrada Quarterly Sales Value (US\$/EUR Million), 2020

Figure 15-1: Sarclisa – FDA Approval by Type

Figure 15-2: Sarclisa – FDA Approval & Patent Expiration Year

Figure 15-3: Sarclisa – Price for 5 ml Supply & Price Per ml of 20mg/ml Intravenous Solution (US\$), February'2022

Figure 15-4: Sarclisa – Price for 25 ml Supply & Price Per ml of 20mg/ml Intravenous Solution (US\$), February'2022

Figure 15-5: Sarclisa – Number of Dose Required in Initial & Subsequent Treatment Cycles (Weeks)

Figure 15-6: US - Lemtrada Annual Sales Value (US\$/EUR Million), 2020 & 2021

- Figure 15-7: US - Lemtrada Quarterly Sales Value (US\$/EUR Million), 2021
- Figure 15-8: US - Sarclisa Quarter Sales Value (US\$/EUR Million), 2020
- Figure 15-9: Darzalex – FDA Approval & Patent Expiration Year
- Figure 15-10: Darzalex – Price for 5 ml Supply & Price Per ml of 20mg/ml Intravenous Solution (US\$), February'2022
- Figure 15-11: Darzalex – Price for 20 ml Supply & Price Per ml of 20mg/ml Intravenous Solution (US\$), February'2022
- Figure 15-12: Darzalex – Duration of Dose Interval by Treatment Phase (Weeks)
- Figure 15-13: Darzalex Faspro – FDA Approval & Patent Expiration Year
- Figure 15-14: Darzalex Faspro – Price for 15 ml Supply & Price Per ml of Subcutaneous Solution (US\$), February'2022
- Figure 15-15: Darzalex Faspro – Duration of Dose Interval by Treatment Phase (Weeks)
- Figure 16-1: Keytruda – Patent Expiration Year by Region
- Figure 16-2: Keytruda – FDA Approval Year by Indication
- Figure 16-3: Keytruda – Price for 4ml & 8ml Supply & Price Per ml of Intravenous Injection (US\$), February'2022
- Figure 16-4: Keytruda – Duration of Single Treatment Cycle & Full Treatment of Melanoma & Other Cancers (Weeks), February'2022
- Figure 16-5: Keytruda - Cost of Single & Full Treatment using Solution of Injection (US\$), February'2022
- Figure 16-6: US - Keytruda Annual Sales Value (US\$ Billion), 2017 - 2020
- Figure 16-7: US - Keytruda Quarterly Sales Value (US\$ Million), 2020
- Figure 16-8: Yervoy – US & Europe Exclusivity Expiration Year
- Figure 16-9: Yervoy – FDA Approval Year by Indication
- Figure 16-10: Yervoy - Price for 10ml Supply & Price Per ml 5mg/ml Intravenous Injection (US\$), February'2022
- Figure 16-11: Yervoy – Price for 40ml Supply & Price Per ml 5mg/ml Intravenous Injection (US\$), February'2022
- Figure 16-12: Yervoy – Duration of Single Treatment Cycle & Full Treatment of Metastatic Melanoma & Hepatocellular Carcinoma (Weeks), February'2022
- Figure 16-13: Yervoy – Average Cost of Single Treatment Cycle & Full Treatment of Metastatic Melanoma & Hepatocellular Carcinoma (US\$), February'2022
- Figure 16-14: Yervoy – Average Cost of Single Treatment Cycle, Initial Year & Remaining- Years for Management of Metastatic Melanoma (US\$), February'2022
- Figure 16-15: US - Yervoy Annual Sales Value (US\$ Million), 2021
- Figure 16-16: US - Yervoy Quarterly Sales Value (US\$ Million), 2021
- Figure 16-17: US - Yervoy Quarterly Sales Value (US\$ Million), 2020
- Figure 16-18: Opdivo – FDA Approval by Indication
- Figure 16-19: Opdivo - Patent Expiration Year by Region

Figure 16-20: Opdivo - Price for 4ml Supply & Price Per ml of 10mg/ml Intravenous Injection (US\$), February'2022

Figure 16-21: Opdivo - Price for 10 ml Supply & Price Per ml of 10mg/ml Intravenous Injection (US\$), February'2022

Figure 16-22: Opdivo - Price for 12 ml Supply & Price Per ml of 10mg/ml Intravenous Injection (US\$), February'2022

Figure 16-23: Opdivo - Price for 24 ml Supply & Price Per ml of 10mg/ml Intravenous Injection (US\$), February'2022

Figure 16-24: Opdivo Monotherapy Therapy - Single Treatment Cycle & Full Treatment Average Cost (US\$), February'2022

Figure 16-25: US - Opdivo Annual Sales Value (US\$ Million), 2021

Figure 16-26: US - Opdivo Quarterly Sales Value (US\$ Million), 2021

Figure 16-27: US - Opdivo Quarterly Sales Value (US\$ Million), 2020

Figure 16-28: Imfinzi – FDA Approval Year by Indication

Figure 16-29: Imfinzi – FDA Approval & Patent Expiration Year

Figure 16-30: Imfinzi – Price for a Supply of 2.4ml & Price Per ml of Solution for Injection (US\$), February'2022

Figure 16-31: Imfinzi – Price for a Supply of 10 ml & Price Per ml of Solution for Injection (US\$), February'2022

Figure 16-32: Imfinzi - Average Cost of Single Treatment Cycle & Full Treatment of NSCLC (US\$), February'2022

Figure 16-33: US - Imfinzi Annual Sales Value (US\$ Million), 2019 - 2021

Figure 16-34: US - Imfinzi Quarterly Sales Value US\$ Million), 2021

Figure 16-35: US - Imfinzi Quarterly Sales Value US\$ Million), 2020

Figure 16-36: Bavencio – FDA Approval Year by Indication

Figure 16-37: Bavencio - Price for 10ml Supply & Price Per ml of 20mg/ml Intravenous Injection (US\$), February'2022

Figure 16-38: Bavencio - Average Cost of Single Treatment Cycle & Annual Treatment (US\$), February'2022

Figure 16-39: Tecentriq – FDA Approval Year by Indication

Figure 16-40: Tecentriq - Price for 14ml Supply & Price Per ml of 840mg/14ml Intravenous Injection (US\$), February'2022

Figure 16-41: Tecentriq - Price for 20ml Supply & Price Per ml of 1200mg/20ml Intravenous Injection (US\$), February'2022

Figure 16-42: Tecentriq - Average Cost of Single Treatment Cycle & Annual Treatment using 840mg/2 Week Dose (US\$), February'2022

Figure 16-43: Tecentriq - Average Cost of Single Treatment Cycle & Annual Treatment using 1200mg/3 Week Dose (US\$), February'2022

Figure 16-44: Tecentriq - Average Cost of Single Treatment Cycle & Annual Treatment

using 1680mg/4 Week Dose (US\$), February'2022

Figure 16-45: US - Tecentriq Annual Sales Value (US\$/CHF Million), 2018 - 2021

Figure 16-46: US - Tecentriq Quarterly Sales Value (US\$ Billion), 2021

Figure 16-47: US - Tecentriq Quarterly Sales Value (US\$ Million), 2020

Figure 16-48: Libtayo – FDA Approval Year by Indication

Figure 16-49: Libtayo – Price for a Supply of 7ml & Price Per ml of Solution for Injection (US\$), February'2022

Figure 16-50: Libtayo – Cost of Single Treatment Cycle & Annual Treatment Cost (US\$), February'2022

Figure 16-51: US - Libtayo Quarterly Sales Value (US\$ Million), 2018 - 2021

Figure 16-52: US - Libtayo Quarterly Sales Value (US\$ Million), 2021

Figure 16-53: US - Libtayo Quarterly Sales Value (US\$ Million), 2020

Figure 16-54: Jemperli – Price for a Supply of 10ml & Price Per ml of Solution for Injection (US\$), February'2022

Figure 16-55: Jemperli - Average Dose of Initial 4 Cycles & Subsequent Cycles (mg)

Figure 16-56: Jemperli - Average Cost of Initial 4 Cycles & Subsequent Cycles (US\$), February'2022

Figure 16-57: US - Jemperli Quarter Sales Value (US\$/GBP Million), Q3 & Q4'2021

Figure 17-1: Erbitux - Approval Year by Cancer Type

Figure 17-2: Erbitux - Price for a Supply of 50 ml & Per unit Price of Intravenous Solution (US\$), February'2022

Figure 17-3: Erbitux - Price for a Supply of 100 ml & Per unit Price of Intravenous Solution (US\$), February'2022

Figure 17-4: Cetuximab – Initial & Maintenance Dose for Colorectal Cancer & Head and Neck Cancer (mg/ m²)

Figure 17-5: Cetuximab – Recommended Dose & Reduced Dose (mg/ m²)

Figure 17-6: US – Nectinumab FDA Approval & Patent Exclusivity Year

Figure 17-7: Portrazza - Price for 50ml Supply & Price per unit of 16mg Intravenous Solution (US\$), February'2022

Figure 17-8: Portrazza – Minimum Dose & Maximum Dose (in mg)

Figure 17-9: Vectibix - FDA Approval & Patent Expiration Year

Figure 17-10: Vectibix – Price for a Supply of 5 ml & Price Per ml of Intravenous Solution (US\$), February'2022

Figure 17-11: Vectibix – Price for a Supply of 20 ml & Price Per ml of Intravenous Solution (US\$), February'2022

Figure 17-12: Vectibix – Cost of Single Treatment Cycle & Annual Treatment Cost for Colorectal Cancer (US\$), February'2022

Figure 17-13: US – Vectibix Annual Sales (US\$ Million), 2019 - 2021

Figure 17-14: US – Vectibix Quarterly Sales (US\$ Million), 2021

- Figure 17-15: US - Vectibix Quarterly Sales Value (US\$ Million), 2020
- Figure 18-1: Phesgo – Price for various Supplies of Subcutaneous Solution for Injection (US\$), February'2022
- Figure 18-2: Phesgo – Duration of Treatment by Type (Cycles)
- Figure 19-1: ELZONRIS – Average Cost for Single Treatment Cycle & Annual Treatment Cost (US\$), February'2022
- Figure 19-2: Monjuvi – Number of Dose per Treatment Cycle by Phase
- Figure 19-3: Monjuvi – Duration of Single Treatment Cycle & Full Treatment (Weeks)
- Figure 19-4: Monjuvi – Cost of Single Dose, Single Treatment Cycle & Full Treatment (US\$), February'2022
- Figure 19-5: US - Monjuvi Annual Sales Value (US\$ Million), 2020 & 2021
- Figure 19-6: US - Monjuvi Quarterly Sales Value (US\$ Million), 2021
- Figure 19-7: US - Monjuvi Quarterly Sales Value (US\$ Million), Q3 & Q4, 2020
- Figure 19-8: Poteligeo – FDA Approval & Patent Expiration Year
- Figure 19-9: Poteligeo – Price for 5ml Supply & Price Per Unit of 4mg/l Intravenous Solution (US\$), February'2022
- Figure 19-10: Poteligeo – Number of Dose Administration in Initial & Subsequent Treatment Cycle
- Figure 19-11: Poteligeo – Cost of Single Dose, Initial & Subsequent Treatment Cycle (US\$), February'2022
- Figure 19-12: Xgeva – Cost of Supply of 1.7ml & Per Unit Price of 120mg Solution (US\$), February'2022
- Figure 19-13: Xgeva – Cost of Single Cycle & Annual Cost of Treatment in Multiple Myeloma (US\$), February'2022
- Figure 19-14: US – Xgeva Annual Sales (US\$ Million), 2019 - 2021
- Figure 19-15: US – Xgeva Quarterly Sales (US\$ Million), 2021
- Figure 19-16: US - Xgeva Quarterly Sales Value (US\$ Million), 2020
- Figure 19-17: Empliciti – Patent Issue & Expiration Year
- Figure 19-18: Empliciti – Price for 300mg & 400mg Supply of Intravenous Powder for Injection (US\$), February'2022
- Figure 19-19: Empliciti – Number of Dose Administration During Initial 2 Cycles & Subsequent Cycles
- Figure 19-20: Empliciti – Cost of Single Cycle during Initial 2 Cycles & Subsequent Cycles (US\$), February'2022
- Figure 19-21: US - Empliciti Annual Sales Value (US\$ Million), 2017 - 2020
- Figure 19-22: US - Empliciti Quarterly Sales Value (US\$ Million), 2021
- Figure 19-23: US - Empliciti Quarterly Sales Value (US\$ Million), 2020
- Figure 19 -24: US – Unituxin FDA Approval & Patent Exclusivity Year
- Figure 19-25: Unituxin – Cost of Supply of 5ml & Per Unit Cost of Intravenous Solution

(US\$), February'2022

Figure 19-26: Unituxin – Cost of Single Cycle & Full Treatment Cost (US\$),
February'2022

Figure 19-27: US – Unituxin Quarterely Sales (US\$ Million), Q1-Q3'2021

Figure 19-28: US – Unituxin Annual Sales (US\$ Million), 2017-2020

Figure 19-29: US – Unituxin Quarterely Sales (US\$ Million), 2020

Figure 19-30: Naxitamab – Cost of Supply of 10ml & Per Unit Cost of Intravenous
Solution (US\$), February'2022

I would like to order

Product name: US Cancer Antibodies Market, Drug Sales, Patent & Clinical Trials Outlook 2028

Product link: <https://marketpublishers.com/r/UD4629618DE3EN.html>

Price: US\$ 3,600.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/UD4629618DE3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970